- Roger Pebody | 04 October 2018
The male partners of adolescent girls and young women in eSwatini (Swaziland) and South Africa report substantial HIV risk behaviours, but the data
also challenge the stereotypical image of a ‘sugar ...
- Gus Cairns | 19 September 2018
For the first time, a US-based professional HIV body
has published guidelines endorsing event-based or so-called ‘on-demand’ pre-exposure
prophylaxis (PrEP) as an alternative to daily dosing.
The International Antiviral Society-USA (IAS-USA) released
its 2018 ...
- Gus Cairns | 28 August 2018
Several studies presented at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam last month detailed very different approaches to introducing pre-exposure prophylaxis (PrEP) to female sex workers (FSWs) as part of combination HIV prevention.The ...
- Michael Carter | 24 August 2018
Dolutegravir-based
antiretroviral therapy (ART) is effective and safe when taken at the same time as
standard tuberculosis (TB) therapy, according to an international study presented at the 22nd International AIDS Conference
(AIDS 2018), ...
- Keith Alcorn | 22 August 2018
A large French study of people taking HIV treatment that
contained an integrase inhibitor found that approximately one person in forty
who started treatment with dolutegravir stopped taking the drug due to
neuropsychiatric ...
- Keith Alcorn | 17 August 2018
Starting treatment on the day of HIV diagnosis is acceptable
and feasible for Thai patients, and people who started treatment very soon after
diagnosis were more than twice as likely to have ...
- Gus Cairns | 13 August 2018
Pre-exposure prophylaxis (PrEP) use is accelerating among men who have sex with men and transgender women in two south-east Asian countries where it is receiving funding and government support, the ...
- Keith Alcorn | 10 August 2018
People on methadone maintenance treatment spent less time
with a detectable viral load above 1500 copies/ml, potentially reducing the
risk of HIV transmission, a study presented at last month’s 22nd
International AIDS Conference ...
- Keith Alcorn | 09 August 2018
Using dolutegravir alone, as maintenance treatment after
achieving undetectable viral load on a three-drug regimen, results in an
unacceptable rate of viral rebound and is unethical in the view of many
experts, the ...
- Liz Highleyman | 08 August 2018
People
living with HIV are about twice as likely to develop steatosis, or fat
accumulation in the liver, even if they don't have hepatitis B or C
co-infection, according to a study presented
at ...
- Roger Pebody | 07 August 2018
A meta-analysis of 38 clinical trials of antiretroviral
therapies (ART) conducted in the past decade found that an average of 17% of
study participants suffered from diarrhoea, with no improvement in more ...
- Gus Cairns | 06 August 2018
This year, 2018, will be the year that a really significant
number of people in Africa started HIV pre-exposure prophylaxis (PrEP), the 22nd International AIDS Conference (AIDS 2018) in Amsterdam heard
last ...
- Liz Highleyman | 01 August 2018
Adolescents and young adults who acquired HIV before or at birth had a 13-fold higher likelihood of developing cancer and a 9-fold higher risk of death, according to a study ...
- Roger Pebody | 01 August 2018
There were significant increases in bacterial sexually
transmitted infections (STIs) in gay and bisexual men taking pre-exposure prophylaxis (PrEP) for the first
time in Victoria, Australia, but infections were concentrated in a ...
- Carole Leach-Lemens | 01 August 2018
The needs for safe conception services and a wider choice of contraception for women living with HIV in sub-Saharan Africa were highlighted last week at the 22nd International AIDS Conference ...
- Liz Highleyman | 31 July 2018
Only 1.5% of people who have used pre-exposure prophylaxis (PrEP) in the United States are aged 17 or younger, and more than 80% of them are girls and young women, ...
- Carole Leach-Lemens | 31 July 2018
Among 60 women presenting to routine antenatal clinics in Kampala, Uganda and Cape Town, South Africa with undiagnosed HIV in late pregnancy, viral load suppression was faster in those starting ...
- Roger Pebody | 30 July 2018
Innovative health promotion interventions engaging men who
have sex with men (MSM) in south east Asia through social media, apps, online
marketing, video tools and phone services were highlighted at the 22nd
International ...
- Michael Carter | 30 July 2018
The experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine was more effective than darunavir/ritonavir over nearly two years of follow-up, according to results of a phase 3 study presented to the ...
- Michael Carter | 30 July 2018
A daily dose of the boosted protease inhibitor darunavir/ritonavir 400/100mg is at least as effective as therapy with lopinavir/ritonavir for people switching treatment while virally suppressed, according to South African ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...